Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune diseases and cancer. Its product candidates include single-chain polypeptide proteins called small modular immunopharmaceuticals (SMIP) that are intended to bind to a specified target cell and elicit specific biological activity in a targeted disease state. The company's principal product candidate is TRU-015, which is in Phase IIb clinical trial for the treatment of rheumatoid arthritis. Its TRU-016 product candidate is directed to CD37, an antigen that is present on B cells, for the treatment of patients with B-cell malignancies, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company, through its collaboration with Wyeth, is also developing TRU-015 for use in multiple indications, such as systemic lupus erythematosus, and B-cell malignancies. Trubion Pharmaceuticals has a strategic collaboration with Wyeth for the development and worldwide commercialization of TRU-015 and other SMIP drug candidates. The company was founded in 1999. It was formerly known as Genecraft, LLC and changed its name to Trubion Pharmaceuticals, Inc. in 2003. Trubion Pharmaceuticals is headquartered in Seattle, Washington.